drug · antibody

DUPIXENT

updated 3mo ago

/ dew-PIL-oo-mab /

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 7

Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 30 investigational indications.

targets

Interleukin-4 receptor subunit alpha

all catalysts(0)

nothing on the calendar yet

Trials studying DUPIXENT

phase2A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)terminatedn=256
—The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitisrecruitingn=184
phase4The Effects of Dupilumab on Allergic Contact Dermatitisactive not recruitingn=17
phase3A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)active not recruitingn=138
phase3A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoidcompletedn=106
phase3A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitisrecruitingn=20
phase4A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.recruitingn=218
phase3Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)active not recruitingn=880

more trials →

News(10)

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
biopharma_dive · 6h ago
Regeneron backs $75M series A for antibody upstart Infinimmune
Infinimmune has amassed further fuel to power its antibody discovery engine, netting a $75 million series A headlined by Regeneron’s venture arm.
fiercebiotech · 1d ago
Braveheart pumps more life into biotech IPO market with $382M expected debut
Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.
biospace · 5d ago
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the q…
biospace · 5d ago
A COPD drug from China draws $115M in venture funding
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
biopharma_dive · 6d ago
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for b…
fiercebiotech · 6d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
biopharma_dive · 11d ago
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its me…
fiercebiotech · 11d ago
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Regeneron and Sanofi said they are in the early stages of discussing areas for further collaboration, building on one of the most fruitful pharmaceutical company partnerships in recent history. An…
endpoints · 12d ago

view all news mentions →

brand

DUPIXENT

trade names

Dupixent, Regn668, sar231893

generic

DUPILUMAB

MOA

12.1 Mechanism of Action Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and both IL-4 and IL-13 signaling through the Type II receptor. Inflammation driven by IL-4 and IL-13 is an important component in the pathogenesis of asthma, AD, CRSwNP, EoE, PN, COPD, CSU, BP, and AFRS. Multiple cell types that express IL-4Rα (e.g., mast cells, basophils, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide, and IgE. The mechanism of dupilumab action has not been definitively established.

indication

1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 ) Allergic Fungal Rhinosinusitis for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who h

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 9m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

DUPIXENT

updated 3mo ago

/ dew-PIL-oo-mab /

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 7

Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 30 investigational indications.

targets

Interleukin-4 receptor subunit alpha

all catalysts(0)

nothing on the calendar yet

Trials studying DUPIXENT

phase2A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)terminatedn=256
—The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitisrecruitingn=184
phase4The Effects of Dupilumab on Allergic Contact Dermatitisactive not recruitingn=17
phase3A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)active not recruitingn=138
phase3A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoidcompletedn=106
phase3A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitisrecruitingn=20
phase4A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.recruitingn=218
phase3Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)active not recruitingn=880

more trials →

News(10)

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
biopharma_dive · 6h ago
Regeneron backs $75M series A for antibody upstart Infinimmune
Infinimmune has amassed further fuel to power its antibody discovery engine, netting a $75 million series A headlined by Regeneron’s venture arm.
fiercebiotech · 1d ago
Braveheart pumps more life into biotech IPO market with $382M expected debut
Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.
biospace · 5d ago
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the q…
biospace · 5d ago
A COPD drug from China draws $115M in venture funding
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
biopharma_dive · 6d ago
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for b…
fiercebiotech · 6d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
biopharma_dive · 11d ago
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
Not content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its me…
fiercebiotech · 11d ago
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Regeneron and Sanofi said they are in the early stages of discussing areas for further collaboration, building on one of the most fruitful pharmaceutical company partnerships in recent history. An…
endpoints · 12d ago

view all news mentions →

brand

DUPIXENT

trade names

Dupixent, Regn668, sar231893

generic

DUPILUMAB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 9m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

DUPIXENT

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying DUPIXENT

News(10)

Report a data issue

comments(0)

DUPIXENT

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying DUPIXENT

News(10)

Report a data issue

comments(0)